Increasing zoonotic disease risks boosting Veterinary API Manufacturing Market
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Increase Is Anticipated For The Anti-Tumor Drugs Market Over The 2026–2030 Period?
The veterinary active pharmaceutical ingredients manufacturing market has experienced robust expansion in recent years. It is projected to increase from $8.03 billion in 2025 to $8.71 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.5%. The historical growth witnessed in this market is attributable to the increasing prevalence of animal diseases, the expanding populations of livestock and companion animals, the flourishing veterinary pharmaceutical industry, the advancement of conventional chemical-based APIs, and a growing demand for anti-infective and antiparasitic drugs.
The veterinary active pharmaceutical ingredients manufacturing market size is projected to experience substantial growth in the upcoming years. It is anticipated to expand to $12.06 billion in 2030, achieving a compound annual growth rate (CAGR) of 8.5%. This growth over the forecast period is attributable to the embrace of biological and recombinant APIs, an increase in contract manufacturing services, the rising need for highly potent APIs, regulatory support for veterinary pharmaceutical production, and a growing emphasis on vaccine API innovations. Prominent trends for the forecast period include the expansion of contract manufacturing for veterinary APIs, the creation of highly potent APIs, an increase in in-house API production capabilities, a heightened focus on anti-infective and antiparasitic APIs, and advancements in vaccine API formulations.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=7942&type=smp
What Underlying Factors Are Accelerating The Growth Of The Anti-Tumor Drugs Market?
The rising occurrence of zoonotic diseases is anticipated to drive expansion in the veterinary active pharmaceutical ingredients manufacturing market. A zoonotic disease, also known as zoonosis, refers to an infectious condition that can naturally spread between animals and humans. The increase in these diseases stems from heightened human-animal interaction, which creates more opportunities for pathogens to transfer from animals to people and establish new infections. Veterinary APIs are utilized in formulating vaccines capable of preventing the spread of zoonotic diseases from animals to humans. Additionally, the application of veterinary APIs can help combat antibiotic resistance, a significant concern in treating zoonotic diseases. For instance, in February 2023, the Council on Foreign Relations (CFR), a US-based independent, nonpartisan member organization, think tank, and publisher, stated that up to 75% of newly discovered or emerging infectious diseases (EIDs) and 60% of recognized infectious diseases originated from zoonotic sources. Worldwide, zoonoses cause 2.7 million human fatalities and 2.5 billion episodes of disease in people each year. Therefore, the growing prevalence of zoonotic diseases is a key driver for the veterinary active pharmaceutical ingredients manufacturing market.
How Is The Anti-Tumor Drugs Market Segmented Across Key Categories?
The veterinary active pharmaceutical ingredients manufacturing market covered in this report is segmented –
1) By Product: Antiparasitic, Anti-Infectives, Vaccines, NSAIDs
2) By Service Type: In House, Contract Outsourcing
3) By Synthesis Type: Chemical Based API, Biological API, Highly Potent API
Subsegments:
1) By Antiparasitic: Endectocides, Anthelmintics, Antiprotozoals
2) By Anti-Infectives: Antibiotics, Antifungals, Antivirals
3) By Vaccines: Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vaccines
4) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Non-Selective NSAIDs, COX-2 Inhibitors
Which Upcoming Trends Are Expected To Influence The Veterinary Active Pharmaceutical Ingredients Manufacturing Market?
Major companies operating in the veterinary active pharmaceutical ingredient manufacturing market are focused on introducing manufacturing plants for APIs to gain a competitive edge in the market. Manufacturing plants for veterinary APIs are facilities that produce active pharmaceutical ingredients used in the formulation of veterinary drugs. For instance, in October 2023, Stallen South Asia Private Limited, an India-based animal health company, launched, unveiled, and started operations at a new veterinary API facility for Halquinol, a non-antibiotic growth promoter belonging to a group of hydroxyquinolines. It is a combination of 5-chloro-8-hydroxyquinoline, 5,7-dichloro-8-hydroxyquinoline, and 7-chloro-8-hydroxyquinoline. Produced products include Halquinol 98%, which is manufactured in accordance with British Pharmacopeia 1980 (BP 80) guidelines. In addition to the more typical 60% and 12%, Stallen is able to sell 98% as a chemical API used in veterinary formulations and feed additives. Stallen wants to lessen the reliance on goods coming from China for the animal health industry by gradually introducing a wide range of APIs from this plant.
Who Are The Dominant Players Shaping The Anti-Tumor Drugs Market Landscape?
Major companies operating in the veterinary active pharmaceutical ingredients manufacturing market are Alivira Animal Health Limited, Excel Industries Limited, Ofichem Group B.V., Jiangsu Lingyun Pharmaceutical Co. Ltd., SUANFARMA S.A., NGL Fine-Chem Limited, FIS – Fabbrica Italiana Sintetici S.p.A., Lupin Limited, Aurobindo Pharma Limited, Saneca Pharmaceuticals AS, Neuland Laboratories Limited, Divi’s Laboratories Limited, Zoetis Inc., Grupo Indukern S.L., Sequent Scientific Limited, Chempro Pharma Private Limited, AMGIS Lifescience Ltd., Huvepharma AD, Vetpharma Animal Health S.L., Qilu Pharma Spain S.A., INDUKERN Chemie AG, Chemopharma S.A., Norbrook Laboratories Limited, Ceva Santé Animale S.A., Vetoquinol S.A., Virbac S.A.
Read the full veterinary active pharmaceutical ingredients manufacturing market report here:
Which Region Is Projected To Dominate The Anti-Tumor Drugs Market During The Forecast Period?
North America was the largest region in the veterinary active pharmaceutical ingredients manufacturing market in 2025. The regions covered in the veterinary active pharmaceutical ingredients manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Anti-Tumor Drugs Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=7942&type=smp
Browse Through More Reports Similar to the Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market 2026, By The Business Research Company
Active Pharmaceutical Ingredients Global Market Report 2026
Veterinary Pharmaceuticals Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/veterinary-pharmaceuticals-global-market-report
Veterinary Pharmaceuticals Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/veterinary-pharmaceuticals-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model